Bringing it all Together for Commercialisation Pt.2

Brian Caine, co-founder and publisher of Bioprocess International Magazine sets out the topic of discussion for the fireside chat, “Bringing it all Together for Commercialisation – perspectives from every stage” and introduces the panel of experts, with conservatively over 100 years of experience between them,

Opening the discussion, Brian explores the problem of cost and time inefficiencies currently causing the industry pain.

“The theme of this discussion is bringing it all together for commercialisation -perspectives from every stage. For many years the biopharmaceutical industry has approached product development upstream, downstream, manufacturing and the supporting analytical methods as a series of separate and independent steps and processes.”

“Many company’s infrastructure has been design to mirror this approach, with each department responsible for only achieving that specific and individual goal. its certainly an approach that still works, but like many things that do work, it may not remain to be the best way or the most efficient way to achieve a goal.

So in today’s competitive environment, the dynamics of biopharmaceutical development are constantly changing and evolving. Technologies are changing, science is changing, the management expectations are changing, so working in process silos doesn’t make as much sense as it used to. And that’s ok, because like in every industry, biopharmaceuticals need to continually evolve and adapt to move forward.

The average price of bringing a new drug to market is now somewhere close to $2.6 billion, and the average time to bring a new drug to market is now around 128 months. This is really too much money, and too much time to sustain success. So in order to mature and grow as a business the biopharmaceutical industry must find a way to reduce overall development cost and time to market.

The key is not to look at upstream and downstream and analytical as separate and independent processes but to look at each phase of development as a complete process. And like parenting, marriage and life, communication is the key to success. All departments need to be on the same page, and agree to the ultimate goal and how to achieve it.

This will ensure the latest science and technologies are being utilised, and synchronised in an approach which should improve efficiency and efficacy and ultimately lower drug development costs and time to market.”

To find out what the panel makes of this, watch part two of our fireside chat below.


One thought on “Bringing it all Together for Commercialisation Pt.2”

Leave a Reply